INTRODUCTION

The coronavirus disease 2019 (COVID-19) is a new infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has reached pandemic status. Although clinical manifestations in patients with COVID-19 are mainly related to the respiratory system, cardiovascular complications have also been identified in the earliest reported cases from Wuhan, the epicenter of the outbreak. \(^1\sim3\) COVID-19 can significantly affect cardiac function and induce cardiac injury. And the latter is associated with increased disease...
several symptoms, including fever, cough, pharyngodynia, fatigue, and complications related to pneumonia, such as acute respiratory distress syndrome and shock. Nevertheless, a brief case report by Inciardi et al. suggests that cardiac involvement may occur in patients with COVID-19 even without signs and symptoms of respiratory tract infection. Cardiac injury in the setting of COVID-19 has attracted extensive attention and follow-up research in the academic community.

Several studies have proved that SARS-CoV-2 infection can induce cardiac injury. Previous studies defined cardiac injury as the serum levels of cardiac biomarkers (eg, troponin I) being significantly associated with higher risk of in-hospital mortality (HR = 5.4, 95%CI 1.6-7.2, p < .001) was the independent risk factor for COVID-19 severity. Furthermore, Shi et al. first demonstrated that cardiac injury was independently associated with an increased risk of mortality in patients with COVID-19 (HR = 3.4, 95%CI 1.6-7.2, p < .001). Subsequently, Wang et al. has drawn a similar conclusion. (Hazard ratio [HR]: 5.4, 95%CI 2.4-12.1, p < .001), with the presence of myocardial injury being significantly associated with higher risk of in-hospital mortality among COVID-19 patients. Guo et al. also found that the prognosis of patients with underlying cardiovascular disease (CVD) but without myocardial injury was relatively favorable, mortality during hospitalization was 7.6% (8/105) in patients without underlying CVD and normal troponin T (TnT) levels, 13% (4 of 30) in those with underlying CVD and normal TnT levels, 38% (6/16) for those without underlying CVD but elevated TnT levels, and 69% (25/36) for those with underlying CVD and elevated TnTs. Together, data from these studies illustrate that the SARS-CoV-2 infection results in varying degrees of cardiac damage, which explains adverse outcomes observed.

Cardiac injury is a common condition among hospitalized patients with COVID-19. However, cardiac biomarker levels reflecting myocardial injury in COVID-19 patients are affected by numerous factors, such as infection, hypoxia, and renal function, there may also be false positives. It is therefore incomplete to evaluate the risk of cardiac adverse events in COVID-19 patients simply by cardiac biomarkers alone.
COVID-19 patients have relatively increased fast heart rates (HR) ranging from 80 to 88 beats per minute (bpm) in sinus rhythm. HR in patients treated in the ICU was faster than whom admitted in the general ward. Nonsurvivors showed significantly faster baseline heart rates on admission compared to survivors. Another study documented heart rate in 17 COVID-19 patients, and tachycardia was found in three patients (17.6%), one of those was a severe case, and two were critical cases. Moreover, two patients in the critical group had AF with elevated ventricular rates between 123 and 160 bpm. One patient had persistent AF whereas the other did not have prior AF. Both passed away from COVID-19. The rising of HR in COVID-19 patients is disproportionate with the increase in the body temperature. Atrial tachyarrhythmias that had not been present on admission was recorded on a subsequent 12-lead ECG in 19 COVID-19 patients (19/115, 16.5%), all admitted to the MICU (27.5% of MICU patients), among them, atrial fibrillation in 12 patients, atrial flutter in 6 patients, and atrial tachycardia in 1 patient. Atrial tachyarrhythmias were common among patients with COVID-19 who required admission to an intensive care unit and were often followed by hemodynamic deterioration.

In short, we have to pay attention to the tachycardias in the severe and critical COVID-19 patients. In addition to exacerbating the previous cardiomyopathy and conduction disorders, inducing arrhythmia events, SARS-CoV-2 may also induce electrophysiological abnormalities in patients with no previous history of heart disease under a variety of mechanisms.

### 3.2 Atrioventricular/intraventricular conduction block

Our recent work reported that the incidence of cardiac arrhythmias in COVID-19 patients ranged from 17% to 30%. Among these, atrioventricular/intraventricular block (11.8%) was the highest incidence in arrhythmia, and the ratio exceeded sinus tachycardia (7.5%), sinus bradycardia (8%), atrial arrhythmias (7%), and ventricular arrhythmias (4%). Complete heart block and severe left ventricular dysfunction were developed in a Child with COVID-19 Infection. Another case from Iran also reported transient complete heart block in a patient with COVID-19, and a 21-year-old female patient ECG showed nonspecific intraventricular conduction delay and multiple premature ventricular complexes.

### 3.3 ST-T changes

In our report, ST-T changes were the most common ECG abnormality in COVID-19 patients, accounting for about 41% (38/93). Five of these patients were diagnosed with acute myocardial infarction (AMI). A recent case series showed 18 patients with COVID-19 who had ST segment elevation in ECG, 13 (72%) patients died in the hospital (acute ST segment elevation myocardial infarction: n = 4, noncoronary myocardial injury: n = 9). A 61-year-old Hispanic male presented with a Brugada-type pattern ECG in right precordial leads, 2 days later he developed a brief episode of atrioventricular nodal reentrant tachycardia (AVNRT). A patient finally died within 24 hours of the occurrence of multifocal ventricular tachycardia (VT) and ST segment elevation.

### 3.4 QT interal prolongation

Our study found a proportion of 13% (12/93) COVID-19 patients had prolonged QT interval, mean QT interval was 431 milliseconds (414-454 milliseconds). QT prolongation has previously been described associated with various conditions (eg, inherited arrhythmia syndromes, myocarditis toxicity, metabolic disorders, certain drugs). Several antimicrobials that are currently used as potential therapeutic agents for COVID-19 have uncertain benefit, and yet may induce electrocardiographic QT prolongation with potential ventricular pro-arrhythmic effects. These agents are chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin, and lopinavir/ritonavir. Recent evidence indicates significant QT prolongation in patients with COVID-19 receiving HCQ. For example, Borba and colleagues performed a parallel, double-blind, randomized clinical trial designed to assess the safety of CQ in dosages, they found that prolongation of QTc interval was observed in 4 of 36 patients (11.1%) in the low-dose group (ie, 450 mg twice daily on day 1 and once daily for 4 days) and 7 of 37 patients (18.9%) in the high-dose group (ie, 600 mg CQ twice daily for 10 days); in addition, 2 patients in the high-dose group (2.7%) experienced ventricular tachycardia, 60% (3/5) patients in the high-dose group with underlying heart disease died. Moreover, the patients who received HCQ with concurrent treatment of azithromycin were at high risk of greater changes in QTc, 12% of them manifested critical QTc prolongation, and the combination caused greater prolongation than either drug alone. For example, Chorin et al observed QTc prolongation from a baseline average of 435 ± 24 milliseconds to 463 ± 32 milliseconds (P < .001), which was observed 3.6 ± 1.6 days after administration of HCQ + azithromycin therapy. In a subset of those patients (9/84, 11%), QTc was severely prolonged to >500 milliseconds, a known ECG marker of high risk of malignant arrhythmia and sudden cardiac death. A greater proportion of patients receiving HCQ+azithromycin experienced cardiac arrest (15.5%) and abnormal ECG findings (27.1%), as did those in the HCQ alone group (13.7% and 27.3%, respectively), compared with azithromycin alone (6.2% and 16.1%, respectively).

Certain antifungal drugs, glucocorticoids and certain antiarrhythmic drugs lead to prolonged QT intervals as well. If these medications are used, clinicians should monitor the patient for side effects, especially prolonged QTc interval by continuous ECG monitoring.
3.5 | Malignant arrhythmias

COVID-19 patients generally have comorbidities that can increase the risk of serious arrhythmias. Malignant arrhythmias in COVID-19 were first described by Guo and colleagues, who reported a 5.9% (11/187) incidence of malignant arrhythmias, including VT/ventricular fibrillation (VF). Also, Du et al reported a large series of patients who died from COVID-19, and found that common cause of death in 7 of the 81 patients was cardiac arrest (8.64%), followed by acute coronary syndrome (4.94%) and malignant arrhythmias (2.47%). In adjusted models with those receiving HCQ or azithromycin as comparison, cardiac arrest was more likely in patients receiving HCQ + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]; E-value = 1.31). SARS-CoV-2 can cause a variety of ECG changes, similar to SARS-CoV. By contrast, SARS-CoV-2 is more likely to induce atrioventricular/intraventricular conduction block, QT interval prolongation, which may lead to a higher risk of malignant ventricular tachyarrhythmias.

At present, the ECG data of COVID-19 patients are limited, and there are discrepancies in terms of the reported rates of various arrhythmia types among the different studies. This is likely the result of the nonhomogeneous characteristics of selected cases among studies, small sample size, region of origin, and the lack of continuous ECG monitoring data. A single ECG evaluation is not comprehensive. Dynamic ECG monitoring is required to better identify the type of arrhythmias. The available data indicate that the clinical course of COVID-19 develops rapidly, the ECG abnormalities detected during hospital stay may be used as a predictor for the severity of disease. If any critical COVID-19 patient has pathophysiological changes similar to fulminant myocarditis, or ECG abnormalities such as conduction block, QT interval prolongation, and ventricular arrhythmia, they probably have a poor prognosis. It is therefore recommended that clinicians should perform a comprehensive evaluation through combining cardiac injury biomarkers, ECG dynamic changes and cardiac imaging, and be alert to life-threatening ventricular arrhythmia storms.

4 | PUTATIVE MECHANISMS OF ARRHYTHMIAS IN SARS-COV-2

A summary of the potential mechanisms by which cardiac arrhythmias occur in SARS-COV-2 infections is shown in Figure 1.

First, SARS-COV-2 may induce injury to cardiomyocytes directly. SARS-COV-2 virus can be internalized after binding to the ACE2 surface receptor on cell membranes, facilitated by the membrane binding proteases of transmembrane serine protease 2 (TMPRSS2) by cleaving the virus S protein. Once inside the cell, coronaviruses replicate using a number of host molecular machinery, such as the NF-κB pathway. Activated NF-κB can affect mRNA expression of pore-forming subunit of fast transient outward potassium current (Ito,f), which can promote arrhythmia by affecting action potential (AP).

Second, SARS-COV-2 may induce cell death. Recent studies have shown that after SARS-COV-2 infection of human bile duct epithelial cells, the expression of genes related to “positive regulation of cell death” and “cell response to external stimulation” such as CD40, caspase recruitment domain family member 8 (CARD8) and serine/threonine kinase 4 (STK4) were significantly up-regulated to induce cell death. We speculate that an analogous mechanism may operate in cardiomyocytes. Previous tissue visualization has revealed irregular shape of the myocardium, darkened cytoplasm, mild fibrosis, and mild hypertrophy of the myocardium. Finally, myocardial damage may reflect ongoing myocarditis and could induce arrhythmias by inducing electrical abnormalities.

Hypoxemia caused by respiratory dysfunction causes a relatively hypoxic environment of the myocardium. Hypoxia can promote cardiomyocyte cell death and affect the function of ion...
channels, leading to alterations in cardiac AP prolongation and/or repolarization, thereby promoting arrhythmogenesis. Hypoxia degrades the expression of the hERG, encoding pore-forming subunit of the fast-activated delayed rectified potassium channel (I_{Kr}), by secreting calopersin, which reduces the I_{Kr}. Moreover, late sodium current (I_{Na}) is increased under hypoxia. Together, ventricular repolarization may be prolonged, leading to reentrant arrhythmias. By contrast, a shortening in repolarization time caused by small-conductance Ca^{2+}-activated K^{+} (SK) channels may also be pro-arrhythmic, especially where there is accompanying shortening in the effective refractory periods. This would be expected to reduce cardiac excitation wavelength in turn predisposing to reentrant activity.

Pro-inflammatory cytokines usually increased in COVID-19 patients, and cytokine storms have been reported in severe cases. These cytokines include IL-6 and IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1, CCL3, and TNF-α. Acute administration of IL-6 significantly increased L-type Ca^{2+} current (I_{CaL}) density and higher amplitudes/durations of calcium transients in ventricular cardiomyocytes. Long-term exposure to IL-6 significantly down-regulated the expression level of Ca^{2+}-ATPase (SERCA2A) gene in neonatal rat ventricular myocytes, which affected intracellular Ca^{2+} level. These studies suggest that IL-6 may affect cardiac AP in multiple ways. In addition, there was a significant correlation between IL-6 level and P wave index. Moreover, IL-6 can down-regulate atrial myocyte junction proteins causing atrial electrical remodeling. Thus, increased IL-6 in COVID-19 patients may affect AP and electrical conduction leading to arrhythmias. IL-1β extends the APD by reducing I_{Kr} current, increasing CaMKII oxidation/phosphorylation and Ca^{2+} spark frequency, promoting arrhythmia. Also, IL-2 increases the peak I_{Na} density by increasing the transcriptional level of SCN3B, encoding the sodium channel, which leads to a decrease in the AP maximum upstroke velocity and ultimately promotes arrhythmia. TNF-α significantly decreased the I_{Kr} density in ventricular myocytes by altering the type of reactive oxygen species, thereby prolonging APD. In addition, TNF-α also reduced I_{CaL}, intracellular calcium transients. Moreover, TNF-α may reduce the expression of SERCA2a by inducing the level of DNA methyltransferase. Therefore, TNF-α signaling is also an important inflammatory factor leading to arrhythmia.

Patients with COVID-19 often present with fever. In the patients with some underlying heart diseases, fever can trigger ventricular fibrillation. It may be related to ion channel mutations, such as SCN5A in Brugada syndrome. Besides, abnormal sodium current also plays an important role. In addition, fever can cause tachyarrhythmias in individuals without inherent heart disease. Its presence may alter the efficacy of sodium channel blockers in terms of their antiarrhythmic effects.

SARS-COV-2 may induce myocardial injury by inhibiting the activity of ACE2. It is thought that ACE2 could be internalized and shed from the membrane surface diminishing function of ACE2 when SARS-COV-2 binding to ACE2 to enter cells. The conversion of angiotensin II (Ang II) to Ang (1-7) may be reduced, which weakens the cardiovascular protection effect of Ang (1-7) through the Mas receptor. For example, Ang1-7 could change I_{CaL}, Ito, expression of Kv4.3 potassium channel, and Ca^{2+} channel to prevent AF ionic remodeling. Besides, Ang II induces automatic activities by activating IP3 receptors and Na^{+}-Ca^{2+} exchanger in guinea pig pulmonary vein myocardium. In addition, chronic Ang II exposure induces ROS production by NOX2 resulting in oxidative activation of CaMKII, further promotes SR- Ca^{2+} leakage, thus increasing the possibility of delayed after depolarization (DAD). Ang II induces membrane depolarization and activation of I_{CaL}. The accumulation of Ang II promotes myocardial fibrosis and cardiac remodeling. These will promote the occurrence of arrhythmias.

Many patients have disorders of coagulation and fibrinolytic system, showing hypercoagulability of blood, and even disseminated intravascular coagulation (DIC). The effects of hypercoagulation on the myocardium, such as acute coronary syndrome, will be ischemia and hypoxia, leading to cardiac electrophysiological abnormalities. It has been changed that Na^{+}–Ca^{2+} exchange, I_{Kr} current, and phosphorylation of proteins in the sarcoplasmic reticulum. Next, early and late depolarization, inducing ectopic beats, and the APD changed. All these will promote the development of reentrant arrhythmias such as malignant ventricular arrhythmia. In addition, acute left atrial ischemia led to ATP-sensitive potassium current (IKATP) conductor-dependent shortened APD, as well as spontaneous focal discharges and reentry loops. Chronic atrial ischemia/infarction promoted atrial fibrillation by unprompted ectopy and sustained reentry.

Administration of certain drugs may affect the electrophysiological properties of the myocardium. For example, the recently controversial CQ and HCQ can cause prolongation of QT interval. In sinoatrial node (SAN) myocytes, HCQ decreased spontaneous action potential firing rate and the “funny” current (I_{f}), and it also affected I_{CaL} and I_{Kr}. These changes caused a delay in the depolarization, thus lowering the heart rate. In addition, azithromycin can also affect the occurrence of AP promoting arrhythmias in cardiomyocytes. It is reported that azithromycin can inhibit I_{CaL}, I_{Kr}, and I_{f}, current, causing bradycardia. However, azithromycin can increase I_{Na} currents in cardiomyocytes with chronic (24 hour) exposure. Moreover, azithromycin promoted the production of reactive oxygen species in cardiomyocytes, mitochondrial damage, inducing cardiac dysfunction and eventually arrhythmia occurs.

Together, a number of ion channels can be adversely affected in COVID-19, leading to alterations in cardiac conduction and/or repolarization properties, as well as calcium handling, which can predispose to cardiac arrhythmogenesis.

### 5 | MANAGEMENT STRATEGIES OF ARRHYTHMIAS IN SARS-COV-2

#### 5.1 | Clinical manifestations and diagnosis

Clinicians should be vigilant of potential rhythm disturbances in COVID-19. Palpitation has been reported as the initial symptom in...
7% (10/137) of COVID-19 patients. Around 4% of COVID-19 patients have a prior history of cardiac arrhythmias and may be particularly susceptible to further rhythm disorders. Therefore, there is a need to determine essential clinical information, such as a history of arrhythmias, unexplained syncope, family history of premature sudden cardiac death, as well as a detailed medication history, especially medications that can induce electrocardiographic QT prolongation, and baseline ECGs. Patients with underlying cardiovascular diseases require attention to their ECG abnormalities and potential risk of cardiac arrhythmias, so as to prevent adverse clinical events.

Baseline examination is necessary to evaluate the hospitalized patients or those who may be at higher risk for cardiac arrhythmias. If the patients with COVID-19 present with palpitation, dizziness, or even unexplained syncope, monitoring for cardiac arrhythmias should be performed. If baseline ECG examination reveals a moderately prolonged QTc, optimization of medications and electrolytes may permit therapy. If the QTc is markedly prolonged, medications which further prolong it should be avoided, or expert consultation may permit administration with mitigating precautions.

ECG should be closely monitored for early warning and intervention. During the pandemic, avoidance from nonessential testing, including serial ECG, reduces exposure of frontline medical workers and other patients to infectious risks. Therefore, continuous ECG monitoring should be applied more in patients with COVID-19, especially in the patients with cardiac comorbidities. Some other experts suggest that it may be feasible to use a handheld ECG device and mobile continuous telemetry monitor (MCOT) as a QT screening tool in patients with COVID-19. Experts from National Center for Gerontology suggest that cardiologists and primary care physicians should pay attention to the following ECG indicators: the ST-T changes accompanied by continuously dynamic changes in two or more leads (I, II, aVF, V5) with R waves domination; new-onset sinus, atrioventricular conduction block, complete right or left bundle branch block, sinus arrest; continuous, coupled, pleomorphic, or multifocal premature contractions; atrioventricular reentrant tachycardia; atrial flutter/atrial fibrillation, QRS complex low voltage, abnormal Q waves and wide QRS complex (QRS > 120ms), continuous ECG monitoring if necessary. Attention should also be paid to whether patients have paroxysmal tachycardia or an increase in pulse rate that does not match the disease severity status. Early identification of high-risk ECG and arrhythmia, and timely intervention are quite important. Bedside temporary cardiac pacemaker and defibrillator monitoring can be helpful.

5.2 Prevention and treatment

Thus far, no specific antiviral drugs or vaccines have been confirmed to benefit COVID-19 except for symptomatic relief and supportive treatments. The treatment guidelines for COVID-19 published by The National Institutes of Health (NIH) determined that no drug(s) has been proven to be safe and effective for treating COVID-19 at present. Although reports have appeared in the medical literature asserting successful treatment of COVID-19 by multiple medications, additional evidence from ongoing clinical trials will be needed to identify the optimal treatment. Several antiviral agents and immunomodulating therapies are currently under clinical investigation.

Moreover, the COVID-19 Treatment Guidelines Panel recommends against the use of the following drugs for the treatment of COVID-19: the combination of HCQ plus azithromycin (AII) because of the potential for toxicities, except in the context of a clinical trial; Lopinavir/ritonavir (AI) or other human immunodeficiency virus (HIV) protease inhibitors (AIII) because of unfavorable pharmacodynamics and negative clinical trial data.

Tempered with concerns of increased risks of QT prolongation and development of TdP, which may be life-threatening, our potential therapeutic options are that it is necessary to discontinue unnecessary medications which may also increase the risk of arrhythmias. If this combination proves to be life-saving for COVID-19 patients, monitoring the QT interval to allow patients to receive combination therapies will be critical.

Certainly, the use of combination therapies with azithromycin and CQ or HCQ in high-risk patients must be carefully weighed against the risks. The higher dosage of CQ (ie, 600 mg CQ twice daily for 10 days) should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. The late sodium channel-blocking drugs like mexiletine have been proposed to be used if the QT interval prolongs. A temporary transvenous pacemaker may be necessary to overdrive pace if the patient is bradycardia with premature ventricular complexes. Careful attention to serum electrolytes, heart rate, and monitoring of QTc intervals may allow administration of a full course of these drugs.

Prevention or treatment of arrhythmias in COVID-19 patients should include optimization of supportive treatments, including bed rest, maintaining water and electrolyte balance, medication or physical cooling in patients with fever, oxygen supplementation in patients with hypoxia or dyspnea, and noninvasive or invasive ventilator support treatment where indicated. For patients with sinus tachycardia, diltiazem or ivabradine may be used for rate management. Diltiazem, propafenone, or verapamil were also considered first in patients with atrial premature beats or tachycardia without cardiac disease. Beta-blockers may promote bronchial smooth muscle spasm and induce asthma adverse reactions, should be used with caution in patients with COVID-19 combined with sinus or atrial tachycardia. If the patient shows sustained VT, intravenous infusion of amiodarone and other antiarrhythmic medications may be given, electrical defibrillation can be used if it necessary. If VF occurs, cardiopulmonary resuscitation should be initiated and defibrillation should be initiated immediately. If patients with severe bradycardia resulting in dizziness, amaurosis, syncope and other symptoms, can be given atropine, isoproterenol, and other drugs to increase the heart rate or a temporary venous pacemaker may be placed. In anticipation of the predicted surge of patients infected with COVID-19 and the need to rationally utilize personal
protective equipment (PPE) while continuing to provide urgent and emergency cardiac interventions, adequate provision of PPE is just the first step.

6 | CONCLUSIONS

Outbreaks of COVID-19 threaten public health but the associated extrapulmonary manifestations and their prolonged consequences are often overlooked. Previous reports reveal that cardiac arrhythmias are one of the common complications associated with COVID-19, which may sometimes be life-threatening. We would suggest that frontline clinicians monitor cardiac rhythm as part of the routine care, and the data may shed light on whether COVID-19-related arrhythmic complications is an independent predictor of adverse outcomes. Early diagnosis and timely treatment to reduce mortality is of crucial importance. Herein, we summarize potential pharmacological and interventional strategies for dealing with this problem. Several medications are currently being tested for their antiviral actions, with potential side effects such as QT prolongation.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ETHICAL APPROVAL
Not required.

ORCID
Gary Tse https://orcid.org/0000-0001-5510-1253
Gregory Y. H. Lip https://orcid.org/0000-0002-7566-1626
Tong Liu https://orcid.org/0000-0003-0482-0738

REFERENCES
1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061. https://doi.org/10.1001/jama.2020.1585. [Epub ahead of print]
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
4. Chen C, Chen C, Yan J, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E008. https://doi.org/10.3760/cma.j.cn12148-20200225-00123. [Epub ahead of print]
5. Wang L, He W, Yu X, Liu HF, Zhou WJ, Jiang H, et al. Prognostic value of myocardial injury in patients with COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;56:E015. https://doi.org/10.3760/ cma.j.cn12148-20200313-00202. [Epub ahead of print]
6. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:9050. https://doi.org/10.1001/jamacardio.2020.0950. [Epub ahead of print].
7. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1017. https://doi.org/10.1001/jamacardio.2020.1017. [Epub ahead of print]
8. Inciardi RM, Lupi L, Zacccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1096. [Epub ahead of print]
9. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81. https://doi.org/10.1016/S2213-2600(20)30079-5. [Epub ahead of print]
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3. [Epub ahead of print]
11. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20(2):124–7. https://doi.org/10.7861/clinmed.2019-coron [Epub ahead of print]
12. He X, Lai J, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E011. https://doi.org/10.3760/cma.j.cn12148-20200228-00137. [Epub ahead of print]
13. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China. medRxiv 2020;2020–2. https://doi.org/10.1101/2020.02.19.20025239. [Epub ahead of print]
14. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Resp Crit Care Med. 2020;201(11):1372–9. https://doi.org/10.1164/rccm.202003-0543OC. [Epub ahead of print]
15. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. https://doi.org/10.1136/bmj.m1091. [Epub ahead of print]
16. Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep 2020; https://doi.org/10.1016/j.jaccas.2020.04.008. [Epub ahead of print]
17. Meyer P, Degrauwwe S, Van Delden C, Ghadri J-R, Templin C, et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020;41(19):1860. https://doi.org/10.1093/eurheartj/ehaa306. [Epub ahead of print]
18. Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861–2. https://doi.org/10.1093/eurheartj/ehaa286. [Epub ahead of print]
19. Kim I-C, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020;41(19):1859. https://doi.org/10.1093/eurheartj/ehaa288. [Epub ahead of print]
20. Li Y, Liu T, Liu M, Li YJ, Yang Y, Zhao J, et al. Electrocardiogram abnormalities in patients with COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;24(2):128–32. https://doi.org/10.3760/ cma.j.cn113859-20200302-00044
21. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with Covid-19 - a Case Series. N Engl J Med. 2020;382(25):2478–80. https://doi.org/10.1056/NEJMc2009020. [Epub ahead of print]
22. Yu CM, Wong RS, Wu EB, Kong S-L, Wong J, Yip GW-K, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4.

23. Luo J, Deng X, Lu Y, Yin Z, Tang X, Yang Z. Preliminary study of myocardial damage in patients with severe acute respiratory syndrome. Zhong Hua Xin Xue Guan Bing Za Zhi. 2003;31(10):723–6.

24. Duan Z, Zhang J, Shen L, Chen Y, Li S. Clinical features and mechanism of heart injury in patients suffered from severe acute respiratory syndrome. Zhong Hua Xin Xue Guan Bing Za Zhi. 2003;31(10):727–30.

25. Li SS, Cheng CW, Fu CL, Chan Y-H, Lee M-P, Chan JW-M, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003;108(15):1798–803.

26. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronavirus and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798–800. https://doi.org/10.1093/eurheartj/ehaa231. [Epub ahead of print]

27. Pan S-F, Zhang H-Y, Li C-S, Wang C. Cardiac arrest in severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4.

28. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–6.

29. Al-Abdallat MM, Payne DC, Aqlasarawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225–33.

30. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21:100331. https://doi.org/10.1016/j.eclinm.2020.100331. [Epub ahead of print]

31. Mehra MR, Desai SS, Kuy SR, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382(25):e102. https://doi.org/10.1056/NEJMoa2007621. [Epub ahead of print]

32. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–93.

33. Hui D, Zhang Y, Yang X, Wang X, He B, Li L, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. medRxiv. 2020-202. https://doi.org/10.1101/2020.02.24.20027052

34. Colon CM, Barrios JG, Chiles JW, McElwee SK, Russell DW, Maddox WR, et al. Atrial arrhythmias in COVID-19 patients. JACC: Clin Electrophysiol. 2020. https://doi.org/10.1016/j.jacep.2020.05.015. [Epub ahead of print]

35. El Assaad I, Hood-Pishcany MI, Kheir J, Mistry K, Dixit A, Halyabar EA. COVID-19 for the cardiologist. JACC: Basic Transl Sci. 2020;5(5):518–36. https://doi.org/10.1016/j.jacbts.2020.04.002. [Epub ahead of print]

36. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17(6):647–9. https://doi.org/10.1038/s41423-020-0426-7. [Epub ahead of print]

37. Uhler C, Shivashankar GV. Mechano-genomic regulation of coronaviruses and its interplay with ageing. Nat Rev Mol Cell Biol. 2020;21(5):247–8.

38. Ali A, Boutjdir M, Arromolaran AS. Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms. Front Physiol. 2018;9:1866.

39. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020;141(24):e906–e907. https://doi.org/10.1161/CIRCULATIONAHA.120.047521. [Epub ahead of print]

40. Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020. https://doi.org/10.1016/j.hrthm.2020.05.014. [Epub ahead of print]

41. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA New Open. 2020; 3(4.23):e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857. [Epub ahead of print]

42. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. doi: https://doi.org/10.1001/jamacardio.2020.1834. [Epub ahead of print]

43. Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: implications for QT interval monitoring [published online ahead of print, 2020 May 28]. J Am Heart Assoc. 2020. https://doi.org/10.1161/JAHA.120.017144. [Epub ahead of print]

44. Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–9. https://doi.org/10.1038/s41591-020-0888-2 [Epub ahead of print]

45. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–https://doi.org/10.1001/jama.2020.8630. [Epub ahead of print]

46. Attri D, Siddiqi HK, Lang JP, Naifull V, Morrow DA, Bohula EA. COVID-19 for the cardiologist. JACC: Basic Transl Sci. 2020;5(5):518–36. https://doi.org/10.1016/j.jacbts.2020.04.002. [Epub ahead of print]

47. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17(6):647–9. https://doi.org/10.1038/s41423-020-0426-7. [Epub ahead of print]

48. Uhler C, Shivashankar GV. Mechano-genomic regulation of coronaviruses and its interplay with ageing. Nat Rev Mol Cell Biol. 2020;21(5):247–8.

49. Ali A, Boutjdir M, Arromolaran AS. Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms. Front Physiol. 2018;9:1866.

50. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020.1007/s13238-020-00718-6. [Epub ahead of print]

51. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007–14. https://doi.org/10.1016/j.modpath.2020.05.014. [Epub ahead of print]

52. Garrott K, Kuzmiak-Glancy S, Wengrowski J, Zhang H, Rogers J, Kay MW, et al. K(ATP) channel inhibition blunts electromechanical decline during hypoxia in left ventricular working rabbit hearts. J Physiol. 2017;595(12):3799–813.
WANG et al.

53. Lamotte SM, Song WJ, Guo J, Li W, Yang T, Baranchuk A, et al. Hypoxia reduces mature HERG channels through calpain up-regulation. FASEB J. 2017;31(11):5068–77.

54. Zeng B, Liao X, Liu L, Ruan H, Zhang C. Thyroid hormone diminishes Ca2+ overload induced by hypoxia/reoxygenation in cardiomyocytes by inhibiting late sodium current and reverse-Na+/Ca2+ exchange current. Pharmacology. 2020;105(1–2):63–72.

55. Tenma T, Mitsuyama H, Watanabe M, Makutani N, Otsuka Y, Mizukami K, et al. Small-conductance Ca (2+) -activated K (+) channel activation deteriorates hypoxic ventricular arrhythmias via CaMKII in cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2018;315(2):H262–H272.

56. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.

57. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–2. https://doi.org/10.1038/s41577-020-0312-7. [Epub ahead of print].

58. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70. https://doi.org/10.1038/s41577-020-0308-3. [Epub ahead of print].

59. Hagiwara Y, Miyoshi S, Fukuda K, Nishiya M, Ikegami Y, Tanimoto K, et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent IGF1 stimulated cardiac hypertrophy. J Mol Cell Cardiol. 2007;43(6):710–6.

60. Lazzarini PE, Laghi-Pasini F, Acampa M, Srivastava U, Bertolozzi I, Giabbanelli B, et al. Systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of interleukin-6-mediated changes in connexin expression. J Am Heart Assoc. 2019;8(16):e11006.

61. Monnerat G, Alarcón ML, Vasconcellos LR, Hochman-Mendez C, Laghi-Pasini F, Acampa M, Srivastava U, Bertolozzi I, Giabbani B, et al. Systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of interleukin-6-mediated changes in connexin expression. J Am Heart Assoc. 2019;8(16):e11006.

62. Zhao Y, Sun Q, Zeng Z, Li Q, Zhou S, Zhou M, et al. Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells. BMC Cardiovasc Disord. 2016;16:1.

63. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z, et al. Impairment of HERG K (+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem. 2004;279(14):13289–92.

64. Vonderlin N, Siebermair J, Kaya E, Köhler M, Rassaf T, Wakili R, et al. Acute regional left atrial ischemia causes accelerated atrial drivers during atrial fibrillation. Heart Rhythm. 2013;10(6):901–9.

65. Nishida K, Qi XY, Wakili R, Comtois P, Chartier D, Harada M, et al. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation. 2011;123(2):137–46.

66. Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12(10):2186–94.

67. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1. No page number.

68. Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, et al. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. Cardiovasc Toxicol. 2017;17(4):344–40.

69. Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol. 2017;10(4). https://doi.org/10.1161/CIRCEP.115.003560.

70. Amin AS, Meregalli PG, Bardai A, Wilde AAM, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med. 2008;149(3):216–8.

71. El-Battrawy I, Lang S, Zhao Z, Akin I, Yücel G, Meister S, et al. Hyperthermia influences the effects of sodium channel blocking drugs in human-induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2016;11(11):e016143.

72. Said M, Becerra R, Valverde CA, Kaetzel MA, Dedman JR, Mundiña-Villena LM, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000. https://doi.org/10.1055/s-0040-1700108. [Epub ahead of print].

73. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–8. https://doi.org/10.1111.jce.14479. [Epub ahead of print].

74. Park DS, Shekhar A, Marra C, et al. FHF2 gene deletion causes intractable electrical storm. Int J Cardiol. 2005;103(2):207–8.

75. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000. https://doi.org/10.1055/s-0040-1700108. [Epub ahead of print].

76. D’Aloia A, Faggiano P, Brentana L, Boldini A, Curnis A, Bontempi L, et al. Small-conductance Ca (2+) -activated K (+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem. 2004;279(14):13289–92.

77. Donnert G, Alarcón ML, Vasconcellos LR, Hochman-Mendez C, Brasil G, Bassani RA, et al. Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat Commun. 2016;7:13344.

78. Zhao Y, Sun Q, Zeng Z, Li Q, Zhou S, Zhou M, et al. Regulation of SCN3B/scn3b by interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells. BMC Cardiovasc Disord. 2016;16:1.

79. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z, et al. Impairment of HERG K (+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem. 2004;279(14):13289–92.

80. Dehmer C, Siebermair J, Kaya E, Köhler M, Rassaf T, Wakili R, et al. Critical inflammatory mechanisms underlying arrhythmias. Herz. 2019;44(2):121–9.

81. D’Aloia A, Faggiano P, Brentana L, Boldini A, Curnis A, Bontempi L, et al. Recurrent ventricular fibrillation during a febrile illness and hyperthermia in a patient with dilated cardiomyopathy and automatic implantable cardioverter defibrillator. An example of reversible electrical storm. Int J Cardiol. 2005;103(2):207–8.

82. Dinckal MH, Davutoglu V, Akdemir I, et al. Incessant monomorphic ventricular tachycardia during febrile illness in a patient with Brugada syndrome: fatal electrical storm. Europace. 2003;5(3):257–61.

83. Park DS, Shekhar A, Marra C, et al. FHF2 gene deletion causes temperature-sensitive cardiac conduction failure. Nat Commun. 2016;7:12966.

84. Amin AS, Meregalli PG, Bardai A, Wilde AAM, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med. 2008;149(3):216–8.

85. El-Battrawy I, Lang S, Zhao Z, Akin I, Yücel G, Meister S, et al. Hyperthermia influences the effects of sodium channel blocking drugs in human-induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2016;11(11):e016143.
87. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. https://doi.org/10.1111/all.14238. [Epub ahead of print].

88. Cheung CC, Davies B, Gibbs K, Laksman ZW, Krahn AD. Multi-lead QT screening is necessary for QT measurement: implications for management of patients in the COVID-19 era. JACC: Clin Electrophysiol. 2020; https://doi.org/10.1016/j.jacep.2020.04.001. [Epub ahead of print].

89. Gabriels J, Saleh M, Chang D, Epstein LM. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. Heart Rhythm Case Rep. 2020;6(5):241–3. [Epub ahead of print].

90. National Center for Gerontology/ National Clinical Research Center for Geriatric Disorders. Expert recommendations for clinical management of myocardial injury associated with coronavirus disease 2019 (first edition). Zhong Guo Xun Huan Za Zhi. 2020;35(4):1–5.

91. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; https://doi.org/10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].

92. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3.

93. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. May 12, 2020. https://covid19treatmentguidelines.nih.gov/.

94. Mitra RL, Greenstein SA, Epstein LM. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine. Heart Rhythm Case Rep. 2020;6(5):244–8. https://doi.org/10.1016/j.hrcr.2020.03.016. [Epub ahead of print].

95. Huang H, Wu G, Zhao Q, Liu Y, Xu Y. Recommendation for the diagnosis and treatment of arrhythmia complicated with COVID-19. Zhong Hua Xin Lu Shi Chang Xue Za Zhi. 2020;24(2):123–27. https://doi.org/10.3760/cma.j.cn.113859-20200304-00052. [Epub ahead of print].

How to cite this article: Wang Y, Wang Z, Tse G, et al. Cardiac arrhythmias in patients with COVID-19. J Arrhythmia. 2020;36:827–836. https://doi.org/10.1002/joa3.12405